雷斯米蒂罗姆:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|May 21, 2024
概括
雷斯米蒂罗姆是一种新的口服THR-β激动剂,已批准用于治疗成年人代谢功能障碍相关的脂肪肝炎 (MASH) 中度至晚期肝纤维化. 这标志着MASH疗法的重大进步.
科学领域:
- 肝病学和内分泌学.
- 药理学和药物开发领域
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH),以前称为NASH,是一种由代谢功能障碍驱动的渐进性肝病.
- 在MASH中,晚期肝纤维化 (F2-F3阶段) 表明肝损伤严重,肝硬化风险增加.
- 目前,晚期纤维化MASH的治疗选择有限,这凸显了针对性治疗的必要性.
研究的目的:
- 要总结resmetirom的发展里程碑,一个口服THR-β激动剂.
- 详细说明美国对MASH治疗的resmetirom的监管批准.
主要方法:
- 综述resmetirom的发展途径,包括临床前和临床研究 (详细信息未提供摘要).
- 分析美国和欧盟的监管提交和审批流程.
主要成果:
- 2024年3月,resmetirom在美国获得加速批准,用于患有非循环性MASH和F2-F3纤维化的成年人.
- 该药物适用于与饮食和运动一起使用.
- 目前,resmetirom正在欧盟对MASH/NASH治疗进行监管审查.
结论:
- 雷斯米蒂罗姆是首个获得批准的针对肝纤维化MASH的潜在原因的治疗方法.
- 批准意味着在管理MASH方面迈出了一大步,MASH是一种具有重大未满足医疗需求的疾病.
- 欧盟正在进行的监管审查可能会扩大对这种新型MASH治疗的准入.
更多相关视频
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.3K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
01:25Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157